The objective of this study was to compare the predictive performance of bleeding risk-estimation tools in a cohort of patients with atrial fibrillation (AF) undergoing anticoagulation.
Background
Three bleeding risk-prediction schemes have been derived for and validated in patients with AF: HEMORR 2 
Methods
We analyzed the dataset from the AMADEUS (Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation) trial, a multicenter, randomized, open-label noninferiority study that compared fixed-dose idraparinux with adjustable-dose oral vitamin K antagonist therapy in patients with AF. The principal safety outcome was any clinically relevant bleeding event, which was a composite of major bleeding plus clinically relevant nonmajor bleeding.
Results
The HAS-BLED score performed best in predicting any clinically relevant bleeding, reflected both in net reclassification improvement (10.3% and 13% improvement compared with HEMORR 2 HAGES and ATRIA, respectively) and receiver-operating characteristic (ROC) analyses (c-indexes: 0.60 vs. 0.55 and 0.50 for HAS-BLED vs. HEMORR 2 AGES and ATRIA, respectively). Using decision-curve analysis, the HAS-BLED score demonstrated superior performance compared with ATRIA and HEMORR 2 HAGES at any threshold probability for clinically relevant bleeding. HAS-BLED was the only score that demonstrated a significant predictive performance for intracranial hemorrhage (c-index: 0.75; p ϭ 0.03). An ATRIA score Ͼ3 was not significantly associated with the risk for any clinically relevant bleeding on Cox regression or on ROC analysis (c-index: 0.50; p ϭ 0.87).
Conclusions
All 3 tested bleeding risk-prediction scores demonstrated only modest performance in predicting any clinically relevant bleeding, although the HAS-BLED score performed better than the HEMORR 2 HAGES and ATRIA scores, as reflected by ROC analysis, reclassification analysis, and decision-curve analysis. Only HAS-BLED demonstrated a significant predictive performance for intracranial hemorrhage. Given its simplicity, the HAS-BLED score may be an attractive method for the estimation of oral anticoagulant-related bleeding risk for use in clinical practice, supporting recommendations in international guidelines. (3) .
In the present study, the relative predictive values of these 3 tools used for AF bleeding risk assessment were compared in a post hoc analysis of data from warfarin-treated patients in the AMADEUS (Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation) trial. We tested the hypothesis that HAS-BLED would perform at least as well as the (older, more complex) HEMORR 2 HAGES and new (weighted) ATRIA tools in predicting the principal trial safety outcome of clinically relevant bleeding events. Secondary objectives included testing these schemes for the endpoints of major bleeding only and death.
Patients and Methods
Study population. The study design of AMADEUS has been previously described (4) . A detailed description of the study design is provided in the Online Appendix. Calculation of bleeding risk scores. Bleeding risk scores in each patient were estimated on the basis of the definitions used in their validation cohorts (Online Table 1 Values are mean Ϯ SD or n (%). *Defined as Ͼ2-fold increase of alanine aminotransferase and/or aspartate transaminase. †Defined as Ͻ75,000 platelets. ‡Defined as hemoglobin Ͻ13 g/dl in men and Ͻ12 g/dl in women. §CHADS 2 , congestive heart failure, hypertension, age Ͼ75 years, diabetes (1 point for each); stroke (2 points). ʈCHA 2 DS 2 VASc, congestive heart failure, hypertension, age Ն75 years, diabetes, stroke, vascular disease, age 65 to Ͻ75 years, sex category (female) (1 point each; 2 points for age Ն75 years and previous stroke).
CrCl ϭ creatinine clearance; NSAID ϭ nonsteroidal anti-inflammatory drug; SBP ϭ systolic blood pressure; TIA ϭ transient ischemic attack; TTR ϭ time in therapeutic range; VKA ϭ vitamin K antagonist. score; 2) none of the patients had a history of active malignancy, alcohol abuse, or major bleeding at study entry, as these were criteria for exclusion from the trial; and 3) in the absence of data on prior international normalized ratio (INR) control, we used each patient's first 5 INR measurements following study entry to calculate time in therapeutic range. Study endpoints. We used data only from the vitamin K antagonist arm and included events that occurred both in the randomization/on treatment period and in the observational period, which followed for a follow-up of 429 Ϯ 118 days. The principal safety outcome of the trial was any clinically relevant bleeding event, subclassified as major bleeding and clinically relevant nonmajor bleeding. Definitions of the study endpoints are provided in the Online Appendix. Statistical analysis. The prognostic value of each score was determined using Cox proportional hazards analysis. C-indexes were calculated for each of the study endpoints. Net reclassification improvement and decision-curve analysis (DCA) were used to quantify the clinical usefulness of the prediction models. Further details on the statistical methods are provided in the Online Appendix.
Results
The AMADEUS study randomized 2,293 patients to the vitamin K antagonist arm (65% men; mean age: 70.2 Ϯ 9.1 years). In total, 251 (11%) patients experienced at least 1 clinically relevant bleeding event. Thirty-nine (1.7%) patients had at least 1 episode of major bleeding. The demographic and clinical characteristics of the AMADEUS population are summarized in Table 1 . The bleeding event rates in the study population, stratified by the three bleeding estimation schemas, are summarized in Table 2 . The HEMORR 2 HAGES bleeding scheme. Median score in the cohort was 1 (interquartile range: 0 to 1). The predictive performance of HEMORR 2 HAGES for both the study bleeding outcomes was modest, as reflected by c-index of 0.55 and 0.60, for clinically relevant bleeding and major bleeding, respectively (Table 3 , Fig. 1 ). In a Cox regression analysis, a HEMORR 2 HAGES score Ͼ1 was associated with a significantly higher risk of all cause mortality but this score was not associated with bleedingregardless of whether defined as major or clinically relevant bleeding (Table 4 , Online Fig. 1 ). The HAS-BLED bleeding scheme. The median HAS-BLED score in the cohort was 2 (interquartile range: 1 to 2). The predictive performance of HAS-BLED for both the study bleeding outcomes was modest, as reflected by c-index of 0.60 and 0.65, for clinically relevant bleeding and major bleeding, respectively (Table 3 , Fig. 1 AUCs (or C-Indexes) for HEMORR 2 HAGES, ATRIA, and HAS-BLED Scores analysis, a HAS-BLED score Ͼ2 was associated with an 85% higher risk for any clinically relevant bleeding and a 2.4-fold higher risk for major bleeding (Table 4 , Online Fig. 1) . A HAS-BLED score Ͼ2 was also associated with 2.9 fold greater risk of death during the study period ( Table 4) . The ATRIA bleeding scheme. The median ATRIA score in the cohort was 1 (interquartile range: 1 to 3). The predictive performance of the ATRIA schema as reflected by the c-index were 0.50 and 0.61, for clinically relevant bleeding and major bleeding, respectively (Table 3 , Fig. 1 ). On Cox regression analysis, an ATRIA score Ͼ3 was not significantly associated with the risk of any clinically relevant bleeding. An ATRIA score Ͼ3 was associated with a significantly higher risk of all-cause mortality and major bleeding ( Cohen's kappa coefficient revealed poor concordance between ATRIA and the other 2 schemas (kappa: Ͻ0.2) and moderate concordance among HAS-BLED and HEMORR 2 HAGES (kappa: 0.46). Only 56 (2.7%) patients were classified as intermediate/high risk by all 3 scores. Bleeding rates in the latter group were 5.4% and 16.1% for major bleeding and any clinically relevant bleeding, respectively, and the mortality rate was 14.3%.
The HAS-BLED score performed best in predicting any clinically relevant bleeding, reflected both on receiveroperating characteristic (ROC) analyses (Table 5 ) and on net reclassification improvement (Tables 6 and 7) , as well as on Cox regression analysis (Table 4) . On ROC analysis, the HR ϭ hazard ratio; other abbreviations as in Table 2 .
ATRIA score failed to demonstrate a significant predictive value for clinically relevant bleeding (c-index: 0.50; p ϭ 0.87). Using DCA, assuming that a classification of high risk by one of the tests will result in alternative treatment, HAS-BLED was superior to the "treat all alternatively" strategy for a threshold probability of any clinically relevant bleeding of 9% or more (Fig. 2) . The HAS-BLED score was superior to the HEMORR 2 HAGES and ATRIA scores for any threshold probability.
HAS-BLED performed better in predicting major bleeding events, as reflected by the slightly greater c-index, although differences in c-index and net reclassification improvement did not reach statistical significance compared with the other 2 scores (Fig. 1) . With respect to all-cause mortality, HAS-BLED performed better than HEMORR 2 HAGES, as reflected by both c-index and net reclassification improvement, but the difference between HAS-BLED and ATRIA did not reach statistical significance.
With respect to bleeding subtypes, HEMORR 2 HAGES and ATRIA scores did not demonstrate any significant predictive performance when fatal bleeding or intracranial hemorrhage was assessed independently (all, p ϭ NS; full data not shown). HAS-BLED was the only score that demonstrated a significant predictive performance for intracranial hemorrhage (c-index: 0.75; 95% CI: 0.56 to 0.95; p ϭ 0.03).
Discussion
In this study, we compared, for the first time, the HEMORR 2 HAGES, HAS-BLED, and ATRIA scores, in predicting bleeding events in a clinical trial cohort undergoing anticoagulation. We demonstrated a clear advantage of the HAS-BLED score over both the ATRIA and HEMORR 2 HAGES scores. Also, HAS-BLED was the only score to demonstrate a significant predictive performance for intracranial hemorrhage. An ATRIA score Ͼ3 was not significantly associated with the risk for any clinically relevant bleeding event on Cox regression or ROC analysis.
This comparison is of practical importance because bleeding risk-scoring systems are featured in management guidelines for stroke prevention in AF. The HAS-BLED scheme is recommended by the European Society of Cardiology and Canadian guidelines (5-7). The HAS-BLED score was also highlighted in the recent Royal College of Physicians of Edinburgh United Kingdom Consensus Conference on Atrial Fibrillation (7).
In our analyses, the 3 bleeding scores exhibited weak discriminatory capacity for both bleeding outcomes, as reflected by c-indexes below 0.70. Bleeding risk estimation has always been challenging and far more complicated than thromboembolic risk estimation. Even in validation cohorts
Comparison of AUCs or C-Indexes for HEMORR 2 HAGES, ATRIA, and HAS-BLED Scores Tables 2 and 3 .
Reclassification Abbreviations as in Table 2 . for HAS-BLED, and 5 for ATRIA). However, the c-index is not the only parameter to be taken into consideration in determining the utility or predictive ability of riskestimation schemas (8) . From the clinical perspective, reclassification analysis seems to be of greater importance, especially for patients reclassified correctly from lowintermediate risk to high risk, as these patients will be considered for alternative treatment.
With respect to the principal outcome of any clinically relevant bleeding, the ATRIA score failed to demonstrate any additional predictive value over chance alone, whereas HEMORR 2 HAGES was slightly better than random stratification. HAS-BLED was significantly better than the other 2 scores in predicting any clinically relevant bleeding. Using DCA, the HAS-BLED score performance was superior to that of HEMORR 2 HAGES and ATRIA with respect to its clinical applicability for whole-spectrum threshold probabilities.
The fact that HAS-BLED exhibited predictive capacity for clinically relevant bleeding should be considered as an advantage, especially because nonmajor clinically relevant bleeding may significantly influence outcome by interrupting or affecting the quality of anticoagulation. Also, only HAS-BLED had a significant (and "good," c-index: 0.75) predictive ability for intracranial hemorrhage, a potential effect of oral anticoagulation. With respect to major bleeding events, all 3 scores demonstrated significant predictive ability, although their c-indexes were below the cutoff point of what is considered good performance (c-index: Ͻ0.70). No statistically significant differences were observed between the 3 scores in the outcome of major bleeding. Mortality prediction. Bleeding risk-prediction schemes were not developed to predict mortality, although major bleeding and mortality are closely related endpoints in populations undergoing anticoagulation (9) . In our analysis, the HAS-BLED score performed best in predicting allcause mortality, as reflected by the c-index, followed by the ATRIA score. The HEMORR 2 HAGES score had the worst performance, probably due to the larger number of bleeding-oriented factors that are used for its calculation. Study limitations. These are results of a post hoc analysis and they should be interpreted as such. The AMADEUS trial population was at relatively low risk for both ischemic stroke and bleeding events compared with patients in clinical practice; patients with a history of major bleeding events or who are at risk for bleeding were excluded from the study. It remains to be established whether these risk scores would have a similar accuracy in clinical practice. Finally, this was a retrospective analysis, and no available trials have evaluated prospectively the impact of the use of these 3 bleeding risk-estimation schemes on patient outcomes (10).
Conclusions
All 3 tested bleeding risk-estimation scores demonstrated only modest performance in predicting the outcome of any clinically relevant bleeding, although the HAS-BLED score performed better than the HEMORR 2 HAGES and We assume that a classification of high risk on one of the tests will result in alternative treatment. If it is considered efficient to apply alternative treatment in 11 patients or less to prevent 1 clinically relevant bleeding event (i.e., threshold probability 9%; dotted arrow), then HAS-BLED is superior to the "treat all alternatively" strategy (gray line) and the "treat none alternatively" strategy (black dotted line). The HAS-BLED score was also superior to the HEMORR 2 HAGES and ATRIA scores for any threshold probability. For a threshold probability of Ͻ9%, the "treat all alternatively" strategy provides the highest net clinical benefit. Abbreviations as in Figure 1 .
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